series-b
Stage
1
Investors
About
iRegene develops first-in-class induced pluripotent stem cell (iPSC) therapies to cure incurable diseases such as Parkinson's Disease, Multiple System Atrophy, and retinal degenerative diseases using advanced gene editing and AI-powered omics discovery platforms.
Explore iRegene's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.